TWD
AQST icon

True Wealth Design’s Aquestive Therapeutics AQST Stock Holding History

True Wealth Design’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-58
Closed -$241 – 2672
2026
Q1 		$241 Hold
58
– – ﹤0.01% 2284
2025
Q4 		$375 Hold
58
– – ﹤0.01% 2045
2025
Q3 		$325 Hold
58
– – ﹤0.01% 2154
2025
Q2 		$192 Buy
58
+30
+107% +$86 ﹤0.01% 2082
2025
Q1 		$82 Buy
+28
New +$85 ﹤0.01% 2261
2024
Q4 		– Sell
-47
Closed -$235 – 1362
2024
Q3 		$235 Buy
+47
New +$183 ﹤0.01% 1184

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

True Wealth Design's AQST Position: Q2 2026 in Review

True Wealth Design sold out of Aquestive Therapeutics (AQST) in Q2 2026, closing a stake of 58 shares — an estimated $241 sold.

True Wealth Design first reported a position in AQST in Q3 2024 and held it in 6 quarters. The position peaked at $375 in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • True Wealth Design reported no remaining Aquestive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • True Wealth Design sold 58 Aquestive Therapeutics shares in Q2 2026, an estimated $241.
  • True Wealth Design first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 6 quarters.
  • True Wealth Design's Aquestive Therapeutics position peaked at $375 in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.